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Introduction
Neonatal tumors occur during the first month of life 
and constitute 2% of all childhood cancers [1]. 
Understanding the distribution and behavior of these 
tumors will enable us to identify the underlying mecha-
nisms, predict survival, and tailor clinical management 
of each disease. The timing of these neoplasms suggests 
a genetic origin [2, 3]. However, few studies have com-
pared the incidence, survival, or treatment modalities 
for patients with neonatal tumors [4, 5]. The outcomes 
of neonatal tumors are diverse. Like some leukemias 
[6, 7], rhabdomyosarcoma [8], and brain tumors [9, 
10], some neonatal tumors have poor prognoses; others 
(neuroblastoma [11] and fibrosarcoma [8]) have better 
ones. Some of the most aggressive tumors (diffuse pon-
tine glioma or high- grade glioma) spontaneously regress 
or are cured by surgical resection only [12, 13], sup-
porting Moore’s theory that some congenital tumors 
mature into benign neoplasms [1]. Treatments vary 
according to center and pathology, and many infants 
with congenital tumors receive no therapy [9]. These 
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Abstract
Neonatal tumors are rare with no standard treatment approaches to these dis-
eases, and the patients experience poor outcomes. Our aim was to determine 
the distribution of cancers affecting neonates and compare survival between 
these cancers and older children. We analyzed SEER data (1973–2007) from 
patients who were younger than 2 years at diagnosis of malignancy. Special 
permission was granted to access the detailed (i.e., age in months) data of those 
patients. The Chi- square Log- rank test was used to compare survival between 
neonates (aged <1 month) and older children (>1 month to <2 years). We 
identified 615 neonatal cancers (454 solid tumors, 93 leukemia/lymphoma, and 
68 CNS neoplasms). Neuroblastoma was the most common neonatal tumor 
followed by Germ cell tumors. The 5- year overall survival (OS) for all neonates 
was 60.3% (95% CI, 56.2–64.4). Neonates with solid tumors had the highest 
5- year OS (71.2%; 95% CI, 66.9–75.5), followed by those with leukemia (39.1%; 
95% CI, 28.3–49.9) or CNS tumors (15%; 95% CI, 5.4–24.6). Except for neu-
roblastoma, all neonatal tumors showed inferior outcomes compared to that in 
the older group. The proportion of neonates who died from causes other than 
cancer was significantly higher than that of the older children (37.9% vs. 16.4%; 
P < 0.0005). In general, the outcome of neonatal cancers has not improved 
over the last 34 years. The distribution of neonatal cancer is different than 
other pediatric age groups. Although the progress in neonatal and cancer care 
over the last 30 years, only death from noncancer causes showed improvement. 
Studying neonatal tumors as part of national studies is essential to understand 
their etiology, determine the best treatment approaches, and improve survival 
and quality of life for those patients.
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factors and the rarity of neonatal tumors make it dif-
ficult to determine the best treatment and factors influ-
encing survival.
The SEER database provides a unique opportunity to 
study rare tumors. Thus, we obtained special permission 
from the SEER administration to analyze monthly data 
not annual data, as is their standard practice.
Materials and Methods
We accessed the 17 SEER databases and analyzed data of 
patients who were <2 years at diagnosis from 1973 to 2007. 
SEER administrators allowed us to access a custom database 
(i.e., with age in months) for patients who presented before 
2 years of age. Only cases with known age and malignancy 
are included in the database. Only cases with malignant 
behavior were included. To extract and analyze data, we 
used SEER*STAT 8.2.1 and IBM SPSS version 20 software, 
respectively [14, 15]. The SEER registries’ composition and 
statistical methods are described elsewhere (http://seer.cancer.
gov/registries/terms.html). International Classification of 
Childhood Cancer (ICCC) was used to group the tumors 
[16]. Cancer types were coded using the International 
Classification of Diseases for Oncology, 3rd Edition (Table 
S1).
For each ICCC group, we calculated frequencies based 
on sex, race, year of diagnosis, and geographic region. 
Secondary cancers were extracted if available. To compare 
survival across eras, we grouped patients into two cohorts: 
1973–1990 and 1991–2007. For more detailed analysis, 
we grouped patients into three cohorts: 1973–1985, 
1986–1998, and 1999–2007 to account for changing in 
treatment eras. Relative frequencies (RFs) were calculated 
for each ICCC category; within each category, RFs were 
calculated for gender. Due to the fact that 17 registries 
did not join SEER at the same decade, these data do 
not reflect incidence or real change of frequency over 
time. Five- year overall survival (OS) was calculated for 
each ICCC category and subgroup, according sex, race, 
year of diagnosis, and region. To avoid statistical bias, 
no statistics were calculated for groups or subgroups with 
fewer than 10 patients. Although this study has the larg-
est neonatal group of cancer patients, the subgroup analysis 
of survival should be considered with caution due to the 
small size of some groups. For this study, survival plateau 
was defined as, “the first point at which the cohort’s OS 
did not change within the subsequent 6 months.” The 
Chi- square Log- rank test was used to compare OS between 
neonates (<1 month) and older patients (>1 month to 
<2 years). For simplicity, we grouped intracranial tera-
tomas with the other germ cell tumors in the solid tumors 
category per ICCC. P < 0.05 was considered 
significant.
Results
There were 615 (310 males) neonates registered with 
malignancies. The number of diagnosed patients decreased 
to 330 at 2 months and 346 at 3 months. The total 
number of patients registered older than 1 month and 
<2 years of age were 7804 patients. Solid tumors were 
the most common diagnosis (n = 454), followed by leu-
kemias/lymphomas (n = 93), and CNS tumors (n = 68). 
Neuroblastoma was the most prevalent tumor (RF = 0.28), 
followed by germ cell tumors (RF = 0.27) (Table 1). 
About 25% of the cases were from the early era (1973–
1990), and the rest were from the later era (1991–2007); 
502 (81.6%) patients were white.
General outcome
The 5- year OS for all neonates was 60.3% (95% CI, 
56.2–64.4). Patients with solid tumors had the highest 
5- year OS (71.2%; 95% CI, 66.9–75.5), followed by leu-
kemia (39.1%; 95% CI 28.3–49.9), and CNS tumors (15%; 
95% CI, 5.4–24.6) (Fig. 1, Table 2, Figure S1 and S2). 
Except for neuroblastoma, all of the neonatal tumors 
showed significantly inferior outcomes compared to that 
in older patients. Lymphoma and hepatoblastoma data 
were removed from further analysis because those sub-
groups included fewer than 10 cases.
The proportion of neonates who died of noncancer 
causes was higher than that of older patients (37.9% vs. 
16.4%; Chi–square P < 0.0005) (Tables S2–S4). Cancer–
specific and noncancer- related OS was significantly better 
in older patients from the later era than in those from 
the earlier era; however, OS did not improve in neonates 
(Fig. 2). Most neonates died within 1 month of diagnosis, 
either from cancer (36.2%) or other causes (59.3%) (data 
not shown, Fig. 3, Table 3). Interventions across eras are 
presented in Figure S3.
Solid tumors
Neuroblastoma
Neuroblastoma was the most common neonatal tumor 
(n = 174, RF = 0.28) in the SEER database. Male neonates 
comprised 60% of patients. The 5–year OS was 76.8% (95% 
CI, 70.3–83.3), with a survival plateau after 30 months (Table 
S6). There was no difference in OS based on sex, race, era, 
or region (Table 2). In cases of neuroblastoma, there was 
no significant difference in survival between neonates and 
the older group (Log–rank P = 0.062) (Table 2).
The adrenal gland was the most common primary 
tumor site, occurring in almost 50% of neuroblastoma 
cases, followed by connective tissue, the retroperitoneum, 
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Table 1. Frequency and relative frequency of neonatal cancers according to broad grouping and ICCC categories.
ICCC Broad Grouping
Gender (RF) Race Era











I Leukemias, myeloproliferative & myelodysplastic 
diseases:
46 (0.54)1 39 (0.46)1 69 16 13 72 85 (0.14)2
I(a) Lymphoid leukemias 12 8 15 5 3 17 20 (0.24)1
I(b) Acute myeloid leukemias 19 23 36 6 7 35 42 (0.49)1
I(c) Chronic myeloproliferative diseases 2 0 2 0 1 1 2 (0.02)1
I(d) Myelodysplastic syndrome and other 
myeloproliferative
1 0 1 0 0 1 1 (0.01)1
I(e) Unspecified and other specified leukemias 12 8 15 5 2 18 20 (0.24)1
II Lymphomas and reticuloendothelial neoplasms 4 (0.50)1 4 (0.50)1 7 1 1 7 8 (0.01)2
II(a) Hodgkin lymphomas 0 1 1 0 0 1 1 (0.13)1
II(b) Non- Hodgkin lymphomas (except Burkitt 
lymphoma)
1 0 1 0 0 1 1 (0.13)1
II(d) Miscellaneous lymphoreticular neoplasms 3 3 5 1 1 5 6 (0.75)1
CNS tumors 
(n = 68)
III CNS and misc intracranial and intraspinal 
neoplasms
35 (0.51)1 33 (0.49)1 58 10 22 46 68 (0.11)2
III(a) Ependymomas and choroid plexus tumor 4 2 4 2 2 4 6 (0.09)1
III(b) Astrocytomas 12 15 22 5 11 16 27 (0.40)1
III(c) Intracranial and intraspinal embryonal tumors 13 13 25 1 7 19 26 (0.38)1
III(d) Other gliomas 4 2 5 1 1 5 6 (0.09)1
III(f) Unspecified intracranial and intraspinal 
neoplasms
2 1 2 1 1 2 3 (0.04)1
Other solid 
tumors 





IV Neuroblastoma and other peripheral nervous cell 
tumors
103 (0.59)1 71 (0.41)1 143 31 58 116 174 (0.28)2
IV(a) Neuroblastoma and ganglioneuroblastoma 103 70 142 31 58 115 173 (0.99)1
IV(b) Other peripheral nervous cell tumors 0 1 1 0 0 1 1 (0.01)1
V Retinoblastoma 13 (0.48)1 14 (0.52)1 21 6 7 20 27 (0.04)2
VI(a) Nephroblastoma and other nonepithelial renal 
tumors
9 (0.56)1 7 (0.44)1 14 2 10 6 16 (0.03)2
VII(a) Hepatoblastoma 4 (0.57)1 3 (0.43)1 6 1 3 4 7 (0.01)2
IX Soft tissue and other extraosseous sarcomas 27 (0.53)1 24 (0.47)1 43 8 16 35 51 (0.08)2
IX(a) Rhabdomyosarcomas 11 8 17 2 8 11 19 (0.37)1
IX(b) Fibrosarcomas, peripheral nerve & other 
fibrous
9 13 17 5 7 15 22 (0.43)1
IX(d) Other specified soft tissue sarcomas 7 3 9 1 1 9 10 (0.20)1
X Germ cell & trophoblastic tumors & neoplasms of 
gonads
63 (0.38)1 105 (0.63)1 134 34 23 143 168 (0.27)2
X(a) Intracranial & intraspinal germ cell tumors 7 13 17 3 0 20 20 (0.12)1
X(b) Extracranial & extragonadal germ cell tumors 55 91 115 31 23 123 146 (0.87)1
X(c) Malignant gonadal germ cell tumors 1 0 1 0 0 1 1 (0.01)1
X(e) Other and unspecified malignant gonadal 
tumors
0 1 1 0 0 1 1 (0.01)1
XI Other malignant epithelial neoplasms and 
melanomas
1 (0.25)1 3 (0.75)1 2 2 2 2 4 (0.01)2
XI(d) Malignant melanomas 1 2 2 1 2 1 3 (0.75)1
XI(f) Other and unspecified carcinomas 0 1 0 1 0 1 1 (0.25)1
XII Other and unspecified malignant neoplasms 2 (0.50)1 2 (0.50)1 4 0 2 2 4 (0.01)2
XII(a) Other specified malignant tumors 1 1 2 0 0 2 2 (0.50)1
XII(b) Other unspecified malignant tumors 1 1 2 0 2 0 2 (0.50)1
Not classified by ICCC 3 0 1 2 1 2 3
Grand Total 310 (0.50)2 305 (0.50) 502 113 158 457
RF, relative frequency; RTh, radiation therapy; Surg, surgery. 
1Relative frequency was calculated as a fraction of the ICCC group. 
2Relative frequency was calculated as a fraction of total cases.
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and the mediastinum. Adrenal gland tumors appeared 
to have the lowest 5–year OS (69.7%; 95% CI, 59.7–79.7), 
but the difference was not significant (Table S5). No 
secondary cancers occurred in neonates with 
neuroblastoma.
Retinoblastoma
The SEER records revealed 27 cases of retinoblastoma 
(RF = 0.04). The 5–year OS of neonates with retinoblas-
toma was 91.7% (95% CI, 80.5–100) (Table 2), with a 
survival plateau after 6 months (Table S6). This group 
experienced the highest OS among the neonatal disease 
subgroups. The OS of older patients who had retinoblas-
toma was significantly better than that of the neonates 
(Log- rank P = 0.043). Only one patient with retinoblas-
toma had secondary cancer.
Nephroblastoma
Renal tumors were also rare (n = 16; RF = 0.03). The 
5–year OS for neonates with nephroblastoma was 62.5% 
(95% CI, 38.8–86.2) (Table 2), with a survival plateau 
after 6 months (Table S6). Older patients had a sig-
nificantly higher OS (87.9%; 95% CI, 85.4–90.4; 
P < 0.001).
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Soft- tissue tumors
Fifty- one neonates had soft- tissue tumors (RF = 0.08)
(Table 1). The 5- year OS for these patients was 52.4% 
(95% CI, 37.5–67.3), with a survival plateau after 
18 months (Tables 2, S6). There was no difference in 
OS on the basis of sex, race, era, or region. Older patients 
with soft- tissue tumors had a significantly higher OS 
(71.5%; 95% CI, 67–76; P = 0.001).
Rhabdomyosarcomas and fibrosarcomas comprised the 
main histologies of soft- tissue tumors in this study. Patients 
with fibrosarcomas had a 5- year OS of 76% (95% CI, 
57.4–94.6), which was significantly higher than that of 
patients with rhabdomyosarcomas (36.3%; 95% CI, 
12.8–59.8) (Table 2). Connective tissue was the most com-
mon primary site of soft- tissue tumors. Fibrosarcomas 
occurred mainly in the limbs, and rhabdomyosarcomas 
occurred mainly in the head and neck (data not shown).
Germ cell tumors
Germ cell tumors were the second- most common neo-
natal tumors in the SEER database (RF = 0.27); 168 
neonates had germ cell tumors, 20 of which were CNS 
tumors. Of the remaining 148 cases, two were gonadal 
and 146 were extragonadal. Female neonates comprised 
62% of cases (Table 1). The 5- year OS of neonates with 
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germ cell tumors was 68.3% (95% CI, 60.7–75.9), with 
a survival plateau after 12 months (Tables 2 and S6). 
The 5- year OS for neonates with extracranial or extrago-
nadal germ cell tumors was 74.5% (95% CI, 66.7–82.3), 
which was significantly higher than that for neonates 
with CNS tumors (25%; 95% CI, 6–44) (Table 2). The 
5- year OS did not differ based on sex, race, era, or 
region. Older patients had a significantly higher OS than 
did the neonates (84%; 95% CI, 79.9–88.1; P < 0.001). 
Two patients with germ cell tumors had secondary 
cancers.
Leukemias
Leukemias comprised 14% of our cohort, of which 49% 
were acute myeloid leukemia (AML), and 24% were acute 
lymphocytic leukemia (ALL) (Table 1). The 5- year OS 
for all leukemia cases was 39.1% (95% CI, 27.9–50.3), 
with a survival plateau after 24 months (Table 2 and S6). 
Patients with AML appeared to have a higher 5- year OS 
than did those with ALL, but the difference was not sig-
nificant (P = 0.403). Survival of the older patients with 
leukemia was 62.8% (95% CI, 60.4–65.2), which was 
significantly higher (P < 0.001) than that of the neonates 
(Table 2). There was no difference in 5- year OS among 
neonates based on sex, race, era, or region. One patient 
suffered a secondary cancer.
CNS tumors
CNS tumors were the fourth- most common tumors affect-
ing neonates in this study (RF = 0.11; Table 1, Table 
S7). Astrocytoma was the most common histology (40%), 
followed by intracranial and intraspinal embryonal tumors 
(38%). Of the 26 intracranial embryonal tumors, 17 were 
PNET, and seven were medulloblastomas (Table S1). The 
5- year OS was 15% (95% CI, 5.4–24.6), with a survival 
plateau after 24 months (Tables 2, S6). Patients with 
astrocytomas had a 5- year OS of 22.9% (95% CI, 5.7–40.1), 
which appeared to be higher than that of those with 
intracranial or intraspinal embryonal tumors (9.4%; 95% 
CI, 0–21.6) (Table 1), but the difference was not signifi-
cant. Survival of the older patients was 58.5% (95% CI, 
55.6–61.4), which was significantly higher than that of 
the neonates (P < 0.001) (Table 2).
Discussion
Tumors rarely arise during the first month of life. In the 
U.K., only 303 neonates with cancer were reported over 
a 3–decade period [4]. To the best of our knowledge, 
this study represents the largest cohort of neonatal cancers 
ever studied. Nevertheless, the increasing number of 
patients over time is related to the fact that the 17 
Figure 3. Comparison of cancer- specific and noncancer- related survival 
between neonates and older patients with cancer.
0.00001
Table 3. Proportion of patients who died of either noncancer- or 
cancer- related causes.
Age Group Cause of death*
TotalNoncancer n (%) Cancer n (5)
Neonate 91 (37.9) 149 (62.1) 240
Older 349 (16.4) 1780 (83.6) 2129
Total 440 (18.6) 1929 (81.4) 2369
*Pearson Chi- Square = 66, P < 0.0005.
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registries are enrolled in the SEER program over the period 
between 1973 and 2000 and pooled their patients gradually 
to the database [17].
Neonates with tumors experienced significantly inferior 
outcome compared with that of older patients who had 
the same disease, except for those with neuroblastoma. 
We believe the one cause of this difference could be treat-
ment denial for newborns. This hypothesis is supported 
by the higher rate of death due to causes other than 
cancer among neonates in our study (Table S4). In our 
study 50.1% of children died of causes other than cancer 
(27% from congenital anomalies and 23.1% from perinatal 
conditions as defined in ICD- 10- CM Guidelines [18]). 
This highlights another limitation of SEER data and our 
study and makes concrete conclusions difficult but it also 
underscores again our plea for further support and wider 
access to detailed data from patients reported on SEER.
Many neonates with tumors probably die of cardiac 
and/or respiratory dysfunction secondary to their untreated 
cancer. One possible explanation is that these infants are 
treated in neonatal intensive care units, and the decision 
to not treat their disease is occasionally made without 
consulting a pediatric oncologist. This explanation requires 
further investigation and conducting wider retrospective 
and prospective studies. Unfortunately, the SEER does 
not provide public access to information (to the time of 
writing this article) on chemotherapy regimens, so we 
cannot conclude anything about the prevalence of that 
approach to treating neonates.
Other studies have documented withholding therapy 
from neonates with cancer. In Isaacs’ study [9] of 154 
children with CNS tumors, 120 were not offered any 
treatment, but the 34 who received any kind of therapy 
experienced superior outcome. However, no quality- of- life 
data were provided.
We are not proposing aggressive treatment of all neo-
nates, especially those with CNS tumors, without consid-
eration of quality of life, or in patients with serious 
comorbidities or congenital anomalies (Table S4) as this 
may cause more harm than benefit. In a study from Japan, 
76% of neonates who survived CNS tumors suffered mental 
retardation [10]. We propose that special attention be 
given to neonates to determine the optimal therapy with 
minimal toxicity (e.g., differentiating agents) that can be 
administered [1, 12, 13].
As reported by others [4], we found a disturbing lack 
of improvement in outcome over the last 34 years in all 
of the neonatal tumors we investigated. The fact that 
even with the major advances in medicine, oncologic 
treatment, supportive care, and neonatology care the out-
come in the third period is not much different than 
30 years earlier underscores that the major hindrance is 
related to age group and not other external factors. In 
older children, survival of every tumor type improved 
every decade. We believe the lack of outcome improve-
ment, despite all the medical advancements, could result 
from depriving many neonates effective (or any) therapy. 
For each tumor group, the outcome of neonates was worse 
than that of older children. A similar observation was 
made in the U.K. neonatal cohort, even in cases in which 
the tumors were associated with a good prognosis [4].
In our study, neuroblastoma was the most common 
neonatal tumor. Most other neonatal cancer studies have 
reported teratomas as the most common neoplasm, fol-
lowed by neuroblastoma [1, 5]. This difference may reflect 
the fact that the SEER registry does not report mature 
teratomas. The 5- year OS in our study was 76.8%, which 
is comparable to that in other studies (74% [19] and 
88.3% [11]). In addition, Isaacs reported improved survival 
between cases before 1983 and those diagnosed thereafter. 
Era did not affect survival in our study.
The second- most common tumor in our study was 
germ cell tumors. The SEER database does not include 
mature or benign tumors before 2004; therefore, it is 
difficult to compare the outcome of those diseases with 
that of such tumors in other studies. Acute leukemias 
are rare in neonates, compared to their incidence in older 
children [20]. The distinction between congenital and 
neonatal leukemia is arbitrary, and most reports discuss 
congenital, neonatal, and infantile leukemias as a single 
group [6, 21]. Our study confirmed that patients with 
neonatal leukemias have a much poorer prognosis than 
older patients and less improvement in outcome, especially 
for those with ALL [4, 6, 7]. AML was the more com-
mon diagnosis than ALL in neonates, which was the case 
in earlier reports [21, 22]. The prognosis of neonates 
with AML was also better than that of neonates with 
ALL, which supports results from all other reports [7, 
21] and contradicts what is seen in older children. This 
difference might reflect the fact that neonatal AML is 
closely related to transient myeloproliferative disorder, 
which shows spontaneous remission in most of cases.
Recently, an update for WHO Classification for Pediatric 
Brain Tumors has removed PNET as an entity from the 
classification and it was integrated in embryonal tumors. 
The diagnoses of this group became dependent on the 
presence C19MC amplification [23]. The new classification 
cannot be retrospectively implemented on the current 
SEER data without access to their histopathology and 
immunohistochemistry panels.
Neonates with cancer died faster than older children 
with cancer either from cancer or noncancer- related causes. 
However, noncancer- related deaths differentiated survival 
between neonatal and older patients. The 30- year OS of 
patients who experienced neonatal cancers equaled that 
of those who experienced cancer at an older age. Survival 
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plateaus can help researchers interpret the crucial periods 
for each tumor entity. We believe that some cancer- related 
deaths that occurred during the first month of life can 
be attributed to insufficient supportive care. Askin [24] 
outlined a supportive care plan for patients with neonatal 
cancer that we believe should be further investigated.
This research could not have been done without the 
SEER administrative team’s approval. We believe that the 
SEER data is a crucial tool toward increasing our under-
standing of rare cancers, although its limitations [25]. For 
example, it would be interesting to investigate the incidence 
of second cancers and familial cancers in these children 
and their families because many believe neonatal tumors 
are indicative of genetic predisposition [2]. Previous studies 
have shown a correlation between congenital anomalies and 
childhood cancers [26–28]. We believe and propose that 
improving funding for SEER to acquire data on comorbidi-
ties, tumor biology, details of received treatments and even 
contacting surviving patients and their families for genetic 
testing or long term effects studies will open the flood 
gates of unlimited research opportunities. The concept of 
wider access to data will only enhance science [29, 30].
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